Advertisement

Re: Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study

  • Joseph M. NorrisEmail author
  • Mark Emberton
  • Clement Orczyk
Letter to Editor
  • 2 Downloads

Keywords

Multiparametric MRI Prostate cancer Targeted biopsy 

Abbreviations

HU

Hounsfield units

mpMRI

Multiparametric MRI

TRUS

Transrectal ultrasound

Notes

Author contributions

JMN: Article conception, manuscript writing. ME: Development of critique, manuscript editing. CO: Development of critique, manuscript editing.

Funding

JMN is funded by the Royal College of Surgeons of England (RCSEng) as an RCS Research Fellow, and previously received support from the National Institute for Health Research (NIHR), The Urology Foundation (TUF), and University College London (UCL).

Compliance with ethical standards

Conflict of interest

The authors declare that there are no potential conflicts of interest.

Ethical standards

None required.

Involvement of human participants and/or animals

Neither human participants or animals were used in the generation of this article.

Informed consent

Informed consent was not required for the generation of this article.

References

  1. 1.
    Lee KS, Koo KC, Chung BH (2018) Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study. World J Urol 36(7):1059–1106CrossRefPubMedGoogle Scholar
  2. 2.
    Cyll K, Ersvær E, Vlatkovic L, Pradhan M, Kildal W, Avranden Kjær M, Kleppe A, Hveem TS, Carlsen B, Gill S, Löffeler S, Haug ES, Wæhre H, Sooriakumaran P, Danielsen HE (2017) Tumour heterogeneity poses a significant challenge to cancer biomarker research. Br J Cancer 117(3):367–375CrossRefPubMedGoogle Scholar
  3. 3.
    Robertson NL, Hu Y, Ahmed HU, Freeman A, Barratt D, Emberton M (2014) Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study. Eur Urol 65(3):628–634CrossRefPubMedGoogle Scholar
  4. 4.
    Wise J (2018) NICE recommends MRI for suspected prostate cancer to reduce biopsies. BMJ 363:k5290CrossRefPubMedGoogle Scholar
  5. 5.
    Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, PROMIS study group (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389(10071):815–822CrossRefPubMedGoogle Scholar
  6. 6.
    Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM, PRECISION Study Group Collaborators (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767–1777CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.UCL Division of Surgery and Interventional ScienceUniversity College LondonLondonUK
  2. 2.Department of UrologyUniversity College London Hospitals NHS Foundation TrustLondonUK
  3. 3.London Deanery of UrologyLondonUK

Personalised recommendations